Phase 1 including first-in-human clinical trials to test biomarker-guided medicines or multi-modal treatment interventions for patients with rare or very rare cancers or cancer subtypes

Expected Outcome: Proposals under this topic should aim to deliver results that are directed and tailored towards, and contribute to all of the following expected outcomes: Patients with rare or very rare cancers or cancer subtypes have access to tailored, promising biomarker-guided medicines or multi-modal treatment interventions via participation in subsequent clinical trials or national or regional compassionate use programmes by health authorities; Researchers, physicians, innovators[1], startup, spin-off and spin-out companies, SMEs, charities or foundations and other professionals from different disciplines and sectors have access to innovative technology, medical devices or promising biomarker-guided medicines for further validation or commercialisation; National healthcare providers, policymakers and authorities in European regions, EU Member States and Associated Countries have early safety and efficacy evidence to support further testing of affordable biomarker-guided medicines or multi-modal treatment interventions that benefit patients with rare or very rare cancers in their healthcare systems; Scope: Patients with rare and very rare[2] cancers across EU Member States and Associated Countries often present with advanced disease due to late diagnosis and have access to few treatment options. Hence, these patients typically have a lower 5-year overall survival than those with more common cancers and face challenges with timely access to a small number of appropriate…bron

De eisen uit de regeling. Uw situatie bepaalt of u voldoet; dit is geen beschikking.

• Phase 1 including first-in-human clinical trials to test biomarker-guided medicines or multi-modal treatment interventions for patients with rare or very rare cancers or cancer subtypesEU-portaal (SEDIA) · ec.europa.eu7 jul 2026
  Toon brontekst

  Phase 1 including first-in-human clinical trials to test biomarker-guided medicines or multi-modal treatment interventions for patients with rare or very rare cancers or cancer subtypes
  
  Topic: HORIZON-MISS-2027-02-CANCER-03
  Call: HORIZON-MISS-2027-02 — Supporting the implementation of the Cancer Mission
  Programma: Horizon Europe (2021 - 2027)
  
  == Beschrijving ==
  Expected Outcome:
  Proposals under this topic should aim to deliver results that are directed and tailored towards, and contribute to all of the following expected outcomes:
  Patients with rare or very rare cancers or cancer subtypes have access to tailored, promising biomarker-guided medicines or multi-modal treatment interventions via participation in subsequent clinical trials or national or regional compassionate use programmes by health authorities;
  Researchers, physicians, innovators[1], startup, spin-off and spin-out companies, SMEs, charities or foundations and other professionals from different disciplines and sectors have access to innovative technology, medical devices or promising biomarker-guided medicines for further validation or commercialisation;
  National healthcare providers, policymakers and authorities in European regions, EU Member States and Associated Countries have early safety and efficacy evidence to support further testing of affordable biomarker-guided medicines or multi-modal treatment interventions that benefit patients with rare or very rare cancers in their healthcare systems;
  Scope:
  Patients with rare and very rare[2] cancers across EU Member States and Associated Countries often present with advanced disease due to late diagnosis and have access to few treatment options. Hence, these patients typically have a lower 5-year overall survival than those with more common cancers and face challenges with timely access to a small number of appropriate phase 1 clinical trials, despite good disease control rates[3], to validate biomarker-guided medicines or multi-modal treatment interventions targeting their disease and adapted to an increasingly precision oncology healthcare landscape.
  Proposals should address all the following:
  When still relevant and required, finalise the preclinical validation of promising[4] biomarker-guided drugs[5], for rare or very rare cancer indications through in vivo and/or ex vivo and/or in silico research models. Drug repurposing should be considered[6]. Data should be disaggregated by tumour biology, sex, gender, age and other relevant variables, such as by measures of socio-economic status or ethnicity;
  Validate early safety and efficacy of innovative medicines or as part of multi-modal treatment interventions in phase 1, including in first-in-human, multi-centre clinical trials, considering new trial designs[7], for and with patients with rare or very rare cancers and their caregivers/families;
  The primary and secondary endpoints of the clinical trial(s) should support safety, efficacy and patient-reported outcomes. Such endpoints should be defined together with patients and their caregivers through research that stimulates social innovation and supports end-user engagement using participative research models.
  All datasets produced should be described with metadata records in the EU dataset catalogue of the European Health Data Space, while all tools and models should take advantage of current European research infrastructures, should follow the principles of open science and made available through the future UNCAN.eu platform;
  Applicants should include proof of advice from regulators on the design of the clinical trial(s), include an appropriate mix of stakeholders from various disciplines, and regional as well as national health authorities, and provide details of the clinical study(ies) in the dedicated annex using the template provided in the submission system;
  Successful proposals will be asked to join the 'Diagnosis and treatment” cluster for the EU Cancer Mission[8] and should include a budget for networking, attendance at meetings, and joint activities[9]. The Commission will facilitate coordination of these activities.
  The successful proposals are expected to build on resources made available by the Knowledge Centre on Cancer (KCC)[10] to foster EU alignment and coordination.
  [1] Innovators turn research results into new and better services and products, to remain competitive in a global marketplace and to improve the quality of life of Europe’s citizens.
  [2] ~24% of all cancers are rare. For definition and incidence of rare cancers see ESMO and RARECARE
  [3] Profile and outcome of cancer patients enrolled in contemporary phase I trials - ScienceDirect
  [4] for example promising efficacy, pharmacokinetics and pharmacodynamics data
  [5] any relevant molecular target, biomarker, therapeutic strategy or technology
  [6] Potential applicants may want to consider ongoing EU-funded efforts like REMEDI4ALL and/or REPO4EU.
  [7] decentralised clinical trials, basket trials, umbrella trials, roll-over/extension trials, adaptive trials
  [8] in order to address the objectives of the EU Cancer Mission, participants will collaborate in project clusters to leverage EU-funding, increase networking across sectors and disciplines, and establish a portfolio of EU Cancer Mission R&I and policy actions.
  [9] Examples of those activities are research or research capacity, organising joint workshops, establishing best practices, joint communication or citizen engagement activities with projects funded under other clusters and pillars of Horizon Europe, or other EU programmes, as appropriate. Proposals are not required to include details of these activities, as they will be defined during the grant agreement preparation and during the life of the project.
  [10] Hosted by the European Commission's Joint Research Centre (JRC). Especially through the ’European Guidelines and Quality Assurance Schemes for Breast, Colorectal and Cervical Cancer Screening and Diagnosis‘, and the ’European Cancer Information System (ECIS)’ and the ’European Cancer Inequalities Registry (ECIR), see https://knowledge4policy.ec.europa.eu/cancer_en.
  
  == Voorwaarden (topic conditions) ==
  ">
  General conditions
  1. Admissibility conditions: Proposal page limit and layout
  described in Annex A and Annex E of the Horizon Europe Work Programme General Annexes.
  Proposal page limits and layout: described in Part B of the Application Form available in the Submission System.
  2. Eligible countries
  described in Annex B of the Work Programme General Annexes.
  A number of non-EU/non-Associated Countries that are not automatically eligible for funding have made specific provisions for making funding available for their participants in Horizon Europe projects. See the information in the Horizon Europe Programme Guide.
  3. Other Eligibility Conditions
  described in Annex B of the Work Programme General Annexes.
  4. Financial and operational capacity and exclusion
  described in Annex C of the Work Programme General Annexes.
  5a. Evaluation and award: Award criteria, scoring and thresholds
  described in Annex D of the Work Programme General Annexes.
  5b. Evaluation and award: Submission and evaluation processes
  The thresholds for each criterion will be 4 (Excellence), 4 (Impact) and 4 (Implementation). The cumulative threshold is 12.
  described in Annex F of the Work Programme General Annexes and the Online Manual.
  5c. Evaluation and award: Indicative timeline for evaluation and grant agreement
  described in Annex F of the Work Programme General Annexes.
  6. Legal and financial set-up of the grants
  Eligible costs will take the form of a lump sum as defined in the Decision of 7 July 2021 authorising the use of lump sum contributions under the Horizon Europe Programme – the Framework Programme for Research and Innovation (2021-2027) – and in actions under the Research and Training Programme of the European Atomic Energy Community (2021-2025) [[This decision is available on the Funding and Tenders Portal, in the reference documents section for Horizon Europe, under ‘Simplified costs decisions’ or through this link: https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/guidance/ls-decision_he_en.pdf]].
  The granting authority may, up to 4 years after the end of the action, object to a transfer of ownership or to the exclusive licensing of results, as set out in the specific provision of Annex 5.
  described in Annex G of the Work Programme General Annexes.
  Specific conditions
  described in the specific topic of the Work Programme
  Application and evaluation forms and model grant agreement (MGA):
  Application form templates
  Please use the application form that you will find in the Submission System. You can find examples of standard application forms in the Reference Documents page.
  Evaluation form templates — will be used with the necessary adaptations
  Standard evaluation form (HE RIA, IA)
  Guidance
  HE Programme Guide
  Model Grant Agreements (MGA)
  Lump Sum MGA
  Call-specific instructions
  Detailed budget table (HE LS)
  Information on clinical studies (HE)
  Guidance: "Lump sums - what do I need to know?"
  Additional documents:
  HE Main Work Programme 2026-2027 – 1. General Introduction
  HE Main Work Programme 2026-2027 – 12. Missions
  HE Main Work Programme 2026-2027 – 15. General Annexes
  HE Framework Programme and Rules for Participation Regulation 2021/695
  HE Specific Programme Decision 2021/764
  EU Financial Regulation 2024/2509
  Decision authorising the use of lump sum contributions under the Horizon Europe Programme
  Rules for Legal Entity Validation, LEAR Appointment and Financial Capacity Assessment
  EU Grants AGA — Annotated Model Grant Agreement
  Funding & Tenders Portal Online Manual
  Funding & Tenders Portal Terms and Conditions
  Funding & Tenders Portal Privacy Statement